Leveraging over a decade of electrophysiology expertise, the NaV1.9 assay, alongside Metrion’s unique combination of ion channel expertise, bespoke assays and pain research services, enables researchers to overcome traditional limitations of NaV1.9 screening and generate reproducible and decision-ready data.

Robust and stable hNaV1.9 cell line delivering high-quality reproducible data allowing rapid hit identification, hit expansion and SAR

Development of robust stably expressing NaV1.9 cell lines (human and rat) validated on high-throughput automated electrophysiology systems

“We’re delighted to work with Emma and look forward to combining her extensive knowledge of K2P channel biology with Metrion’s ion channel discovery knowledge”, commented Dr Eddy Stevens, CSO at Metrion.

How advancements in ion channel drug discovery are developing research in the field of pain management

We are proud to be included in the Business Weekly Killer50 Life Sciences Ones2Watch for 2025

One of the critical contributors to the development of epilepsy is ion channel dysfunction. We focus on a selection of ion channels that can be involved.

Metrion shortlisted as 'Employer of the Year'

Lysosomal ion channels: TRPML1, TRPML2, TRPML3, TMEM175, and TPC2.

Whether you're a small biotech managing tight budgets or a large pharma striving for efficiency, Metrion is here to help you do more with less.